ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Natural Products Inspired Scaffold Diversification Leads to Unnatural Molecular Warhead and Covalent Strategy to Modulating Protein Function through Electrophilic Bromine Transfer.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
We discovered a thiolate-reactive α,α-gem-dibromo lactam warhead that activates transcription factor Nrf2 and demonstrates anti-inflammatory activities, which have implications in cancer, neurodegeneration, and cardiovascular diseases. Our findings originated from new compounds accessed through aza-oxyallyl cation-mediated [3+2]-cycloadditions of ajmalicine and inspired indoles. RNA-seq and Ingenuity Pathway Analysis illuminated detailed transcriptional profiles of α,α-gem-dibromo lactams to show activation of the antioxidant Keap1/Nrf2 pathway and suppressed NF-κB-mediated inflammatory signaling. We demonstrated the importance of the α,α-gem-dibromo lactam, as the corresponding α,α-gem-dichloro lactam is unable to activate the Nrf2 pathway. Chemical reactions with cysteine-containing compounds suggested α,α-gem-dibromo lactams react with cysteine residues to transfer electrophilic bromine to target molecules, linking unique chemistry to our biological findings. In contrast to electrophiles that activate the canonical Nrf2 pathway by covalently targeting C151 of Keap1, the α,α-gem-dibromo lactams function in a C151-independent manner, indicating a distinct selectivity and consequently mode of action. Pharmacological profiling of several α,α-gem-dibromo lactams compared with ajmalicine against adrenergic receptors revealed substantial differences, indicating tunability and novel pharmacology. Future investigations aim to explore the fundamental activities of the dibromo lactam warhead related to human disease. Installation of this warhead into various molecular scaffolds may be a generalizable method to create cystein-reactive electrophiles.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.